dc.contributor.author |
Cho, Kenta Ht |
|
dc.contributor.author |
Davidson, Joanne O |
|
dc.contributor.author |
Dean, Justin M |
|
dc.contributor.author |
Bennet, Laura |
|
dc.contributor.author |
Gunn, Alistair J |
|
dc.coverage.spatial |
Australia |
|
dc.date.accessioned |
2021-08-05T23:06:36Z |
|
dc.date.available |
2021-08-05T23:06:36Z |
|
dc.date.issued |
2020-7-9 |
|
dc.identifier.issn |
1328-8067 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/55868 |
|
dc.description.abstract |
Therapeutic hypothermia is now well established to partially reduce disability in term and near-term infants with moderate-severe hypoxic-ischemic encephalopathy. Preclinical and clinical studies have confirmed that current protocols for therapeutic hypothermia are near optimal. The challenge is now to identify complementary therapies that can further improve outcomes, in combination with therapeutic hypothermia. Overall, anti-excitatory and anti-apoptotic agents have shown variable or even no benefit in combination with hypothermia, suggesting overlapping mechanisms of neuroprotection. Inflammation appears to play a critical role in the pathogenesis of injury in the neonatal brain, and thus, there is potential for drugs with immunomodulatory properties that target inflammation to be used as a therapy in neonates. In this review, we examine the evidence for neuroprotection with immunomodulation after hypoxia-ischemia. For example, stem cell therapy can reduce inflammation, increase cell survival, and promote cell maturation and repair. There are also encouraging preclinical data from small animals suggesting that stem cell therapy can augment hypothermic neuroprotection. However, there is conflicting evidence, and rigorous testing in translational animal models is now needed. |
|
dc.format.medium |
Print-Electronic |
|
dc.language |
eng |
|
dc.publisher |
Wiley |
|
dc.relation.ispartofseries |
Pediatrics international : official journal of the Japan Pediatric Society |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.subject |
Stem Cells |
|
dc.subject |
Animals |
|
dc.subject |
Humans |
|
dc.subject |
Brain Injuries |
|
dc.subject |
Hypoxia-Ischemia, Brain |
|
dc.subject |
Inflammation |
|
dc.subject |
Anti-Inflammatory Agents |
|
dc.subject |
Immunologic Factors |
|
dc.subject |
Combined Modality Therapy |
|
dc.subject |
Hypothermia, Induced |
|
dc.subject |
Infant, Newborn |
|
dc.subject |
Cold Temperature |
|
dc.subject |
Immunomodulation |
|
dc.subject |
Neuroprotection |
|
dc.subject |
hypoxia-ischemia |
|
dc.subject |
inflammation |
|
dc.subject |
neuroprotection |
|
dc.subject |
therapeutic hypothermia |
|
dc.subject |
toll-like receptors |
|
dc.subject |
Animals |
|
dc.subject |
Anti-Inflammatory Agents |
|
dc.subject |
Brain Injuries |
|
dc.subject |
Cold Temperature |
|
dc.subject |
Combined Modality Therapy |
|
dc.subject |
Humans |
|
dc.subject |
Hypothermia, Induced |
|
dc.subject |
Hypoxia-Ischemia, Brain |
|
dc.subject |
Immunologic Factors |
|
dc.subject |
Immunomodulation |
|
dc.subject |
Infant, Newborn |
|
dc.subject |
Inflammation |
|
dc.subject |
Neuroprotection |
|
dc.subject |
Stem Cells |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Pediatrics |
|
dc.subject |
hypoxia-ischemia |
|
dc.subject |
inflammation |
|
dc.subject |
neuroprotection |
|
dc.subject |
therapeutic hypothermia |
|
dc.subject |
toll-like receptors |
|
dc.subject |
STEM-CELL TREATMENT |
|
dc.subject |
NEONATAL-RAT |
|
dc.subject |
OXIDATIVE-METABOLISM |
|
dc.subject |
CEREBROSPINAL-FLUID |
|
dc.subject |
CEREBRAL-ISCHEMIA |
|
dc.subject |
SIGNALING PATHWAY |
|
dc.subject |
ENERGY FAILURE |
|
dc.subject |
MATTER INJURY |
|
dc.subject |
TNF-ALPHA |
|
dc.subject |
HYPOTHERMIA |
|
dc.subject |
1109 Neurosciences |
|
dc.subject |
Biomedical |
|
dc.subject |
Basic Science |
|
dc.subject |
Neurosciences |
|
dc.subject |
Infant Mortality |
|
dc.subject |
Regenerative Medicine |
|
dc.subject |
Perinatal Period - Conditions Originating in Perinatal Period |
|
dc.subject |
Brain Disorders |
|
dc.subject |
Stroke |
|
dc.subject |
Injury (total) Accidents/Adverse Effects |
|
dc.subject |
Pediatric |
|
dc.subject |
Neurological |
|
dc.subject |
5.1 Pharmaceuticals |
|
dc.subject |
1101 Medical Biochemistry and Metabolomics |
|
dc.subject |
1103 Clinical Sciences |
|
dc.subject |
1114 Paediatrics and Reproductive Medicine |
|
dc.title |
Cooling and immunomodulation for treating hypoxic-ischemic brain injury. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1111/ped.14215 |
|
pubs.issue |
7 |
|
pubs.begin-page |
770 |
|
pubs.volume |
62 |
|
dc.date.updated |
2021-07-21T03:54:00Z |
|
dc.rights.holder |
Copyright: The author |
en |
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/32119180 |
|
pubs.end-page |
778 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Review |
|
pubs.subtype |
Journal Article |
|
pubs.elements-id |
805778 |
|
dc.identifier.eissn |
1442-200X |
|
pubs.online-publication-date |
2020-7-9 |
|